Figure 2From: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infantsDetail of the "Prophylaxis, < 33 weeks" branch.Back to article page